PEG-Intron peginterferon alfa-2b: Phase III data; under FDA review and marketed in Europe

ENZN and partner Schering-Plough Corp. (SGP, Kenilworth, N.J.) said data from a 48-week international Phase III trial in 1,530 treatment-naïve patients showed that weekly injections of 1.5 ug/kg PEG-...